Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

1. Lenacapavir: A Review in HIV Pre-Exposure Prophylaxis.Drugs · 2026
   Review
2. Re-evaluating the Potential Impact of Preexposure Prophylaxis (PrEP) in Achieving HIV Elimination in the United States: Insights From Modeling.Open forum infectious diseases · 2026
   Article
3. The Dawn of a New Pharmaceutical Epoch: Can AI and Robotics Reshape Drug Formulation?Advanced healthcare materials · 2024
   Article
4. New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.Viruses · 2024
   Review
5. Development of a CrMikrochimica acta · 2024
   Article
6. Lenacapavir for HIV Prevention in Africa: Opportunities, Barriers, and Policy Priorities.Journal of the International Association of Providers of AIDS Care
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as